Position:
Clinical Instructor
Division:
Hematology
Research Interests:

Development of clinical databases in order to enhance clinical research.

Education:
MBBCh Alfatah University, Tripoli, Libya
MRCPI Royal College of Physicians of Ireland, Dublin, Ireland Internal Medicine
DipRCPath Royal College of Pathologists, London, UK Haematology
FRCPath Royal College of Pathologists, London, UK Haematology
FRCPI Royal College of Physicians of Ireland, Dublin, Ireland Haematology
Recent Publications:
  • Leitch HA, Chase JM, Goodman TA, Ezzat H, Rollins MD, Wong DH, Badawi M, Leger CS, Ramadan KM, Barnett MJ, Foltz LM, Vickars LM. Improved survival in red blood cell transfusion dependent patients with primary myelofibrosis (PMF) receiving iron chelation therapy. Hematol Oncol. 2010 Mar;28(1):40-8.
  • Leitch HA, Leger CS, Goodman TA, Wong KK,  Wong DHC, Ramadan KM, Rollins MD, Barnett MJ, Galbraith PF, Vickars LM. Improved Survival in Patients with Myelodysplastic Syndrome Receiving Iron Chelation Therapy. Clinical Leukemia.20(3):205-211. September 2008.
  • Ramadan KM, Connors JM, Al-Tourah AJ, Song KW, Gascoyne RD, Barnett MJ, Nevill TJ, Shepherd JD, Nantel SH, Sutherland HJ, Forrest DL, Hogge DE, Lavoie JC, Abou-Mourad YR, Chhanabhai M, Voss NJ, Brinkman RR, Smith CA, Toze CL. Allogeneic SCT for relapsed composite and transformed lymphoma using related and unrelated donors: long-term results. Bone Marrow Transplant. 2008 Nov;42(9):601-8. Epub 2008 Aug 11.
  • El-Agnaf MR, McCoy C, Ong Y-L, Eswedi A-H, Black B, Ramadan KM. Infusion of rituximab over 90-minutes on an out-patient basis is safe and improves resource utilization. Leukemia and Lymphoma 2007;48:1875-77.
  • Ramadan K, Eswedi HA, El-Agnaf MR. Schnitzler’s Syndrome: A case report of successful treatment using the anti-cd20 monoclonal antibody rituximab. British Journal of Dermatology 2007;156:1072-1074.
  • Ramadan K, Shenkier T, Sehn L, Gascoyne R, Connors JM. A clinicopathological retrospective study of 131 patients with primary bone lymphoma: a population-based study of successively treated cohorts from the British Columbia Cancer Agency. Annals of Oncology 2007;18:129-135.
  • Knott M, Ramadan K, Savage G, Jones FGC, El-Agnaf  M, Mc Mullin MF, Percy MJ. Novel and Mediterranean beta thalassaemia mutations in the indigenous Northern Ireland population. Blood Cells Molecules and Diseases 2006;36:265-268.
  • Ramadan K, Bowers M, El-Agnaf M, Kettle P. Late-onset post-transplant lymphoproliferative disease: A report of four patients in one center. Leukemia and Lymphoma 2006;47:1191-1193.
  • Ramadan K, Kyle A, McManus D, O’Rourk D, Cuthbert RGJ. Urinary bladder infiltration with chronic B-lymphocytic leukaemia: Two cases with unusual presentation. Leukemia and Lymphoma 2006;47:1184-1187.
  • Ramadan K, McKenna K, Morris TCM Cutaneous Clinical response of cutaneous squamous-cell carcinoma to bortezomib given for myeloma. The Lancet Oncology 2006;7:958-959.
  • Ramadan K, McNulty O, Anderson J, Jones F, Winter P. A novel factor XI gene mutation associated with mild factor XI deficiency in a symptomatic patient. Blood Coagulation and Fibrinolysis 2006;17:499-502.